At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
Regorafenib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
In Brief
A Phase 2 clinical trial evaluating Regorafenib, 5-Fluorouracil, and 2 other interventions for Esophageal Cancer and Gastric Cancer. Completed, enrolled 39 participants across 5 sites.
Detailed Summary
The purpose of this study is to evaluate the effects, good and/or bad, of the drug regorafenib with chemotherapy regime (FOLFOX). This is a a Phase II trial that will study if this new treatment is effective and safe in patients with esophagus and stomach cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer, Gastric Cancer
CountriesUnited States
CollaboratorsBayer
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedAug 2013
Primary CompletionJun 2019
TodayJul 2026
First PostedAug 1, 2013
Enrollment StartJul 1, 2013
Primary CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 12.9 years ago
Interventions
Regorafenibdrug
5-Fluorouracildrug
Leucovorindrug
Oxaliplatindrug